Warren Joubert
YOU?
Author Swipe
View article: 727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours
727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours Open
Background SUPLEXA is a first-in-class, autologous, adoptive immunotherapy; prepared from patients' PBMCs that contains cytolytic populations of NK cells, NKT-like, gd T cells, and ab CD8/CD4 T cells. Methods This is a FIH Phase 1, non-com…
View article: 632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies
632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies Open
Background SUPLEXA is a first-in-class, autologous, adoptive immunotherapy; prepared from patients' PBMCs it contains NK cells, NKT-like, gd T cells, and ab T cells of both the CD8+ and CD4+ variety primed for broad tumor cytolytic activit…
View article: Catheter‐related thrombosis incidence and risk factors in adult cancer patients with central venous access devices
Catheter‐related thrombosis incidence and risk factors in adult cancer patients with central venous access devices Open
Background Central venous access devices (CVAD) are commonly employed in the management of cancer patients. While having several benefits they are associated with significant risks. Aim To review the incidence and risk factors for catheter…
View article: Multidecadal trend analysis of aerosol radiative properties at a global scale
Multidecadal trend analysis of aerosol radiative properties at a global scale Open
In order to assess the global evolution of aerosol parameters affecting climate change, a long-term trend analyses of aerosol optical properties were performed on time series from 52 stations situated across five continents. The time serie…
View article: Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial Open
Cancer Research UK and AstraZeneca.